FR22C1049I1 - CONDENSED HETEROCYCLIC DERIVATIVE SALT AND CRYSTALS THEREOF - Google Patents
CONDENSED HETEROCYCLIC DERIVATIVE SALT AND CRYSTALS THEREOFInfo
- Publication number
- FR22C1049I1 FR22C1049I1 FR22C1049C FR22C1049C FR22C1049I1 FR 22C1049 I1 FR22C1049 I1 FR 22C1049I1 FR 22C1049 C FR22C1049 C FR 22C1049C FR 22C1049 C FR22C1049 C FR 22C1049C FR 22C1049 I1 FR22C1049 I1 FR 22C1049I1
- Authority
- FR
- France
- Prior art keywords
- crystals
- condensed heterocyclic
- heterocyclic derivative
- derivative salt
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/62—Quaternary ammonium compounds
- C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010027806 | 2010-02-10 | ||
| PCT/JP2011/052719 WO2011099507A1 (en) | 2010-02-10 | 2011-02-09 | Salt of fused heterocyclic derivative and crystal thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR22C1049I1 true FR22C1049I1 (en) | 2022-12-09 |
| FR22C1049I2 FR22C1049I2 (en) | 2023-11-24 |
Family
ID=44367777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR22C1049C Active FR22C1049I2 (en) | 2010-02-10 | 2022-09-26 | CONDENSED HETEROCYCLIC DERIVATIVE SALT AND CRYSTAL THEREOF |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US9169266B2 (en) |
| EP (1) | EP2535342B1 (en) |
| JP (1) | JP5337261B2 (en) |
| KR (1) | KR101631143B1 (en) |
| CN (1) | CN102753557B (en) |
| AU (1) | AU2011215250B2 (en) |
| BR (1) | BR112012020110B1 (en) |
| CA (1) | CA2788533C (en) |
| ES (1) | ES2502740T3 (en) |
| FR (1) | FR22C1049I2 (en) |
| IL (1) | IL221325A (en) |
| MX (1) | MX2012009323A (en) |
| NZ (1) | NZ601684A (en) |
| RU (1) | RU2557237C2 (en) |
| SG (1) | SG183243A1 (en) |
| TW (1) | TWI555751B (en) |
| WO (1) | WO2011099507A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014042176A1 (en) * | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | Method for producing fused-heterocyclic derivative, and production intermediate thereof |
| KR102433001B1 (en) * | 2016-08-08 | 2022-08-18 | 깃세이 야쿠힌 고교 가부시키가이샤 | Usage and Dosage of Endometriosis Treatment |
| AU2018280742B2 (en) | 2017-06-05 | 2023-12-21 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| MX2019014482A (en) * | 2017-06-05 | 2020-08-17 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss. |
| EP3873465A2 (en) | 2018-10-29 | 2021-09-08 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| EP3876943A2 (en) | 2018-11-07 | 2021-09-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| EP4009976A1 (en) * | 2019-08-08 | 2022-06-15 | ObsEva S.A. | Gnrh antagonists for the treatment of estrogen-dependent disorders |
| JP2022543308A (en) | 2019-08-08 | 2022-10-11 | オブセヴァ エス．エー． | Compositions and methods for the treatment of estrogen dependent disorders |
| CN115232144B (en) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof |
| AU2023215938A1 (en) | 2022-02-04 | 2024-08-22 | Kissei Pharmaceutical Co., Ltd. | Oral solid preparation |
| WO2024049275A1 (en) * | 2022-09-02 | 2024-03-07 | Rexpharmtech Co., Ltd | Novel benfotiamine choline salt |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56108787A (en) * | 1980-01-31 | 1981-08-28 | Sato Yakugaku Kenkyusho:Kk | Camptothecin coline salt and its preparation |
| US4663348A (en) * | 1985-07-02 | 1987-05-05 | Warner-Lambert Co. | Furosemide salts and pharmaceutical preparations thereof |
| DE3830932A1 (en) * | 1988-09-12 | 1990-03-15 | Diamalt Ag | 2-HYDROXY-N, N, N-TRIMETHYL ETHANAMINIUM SALTS OF 5SS-CHOLAN-24-ACID DERIVATIVES |
| SI1939204T1 (en) * | 2005-10-19 | 2013-05-31 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| CN101331134B (en) * | 2005-10-19 | 2012-11-28 | 橘生药品工业株式会社 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| GB0603522D0 (en) * | 2006-02-22 | 2006-04-05 | Avidex Ltd | Kinase inhibition |
| RU2345996C1 (en) * | 2007-07-17 | 2009-02-10 | Андрей Александрович Иващенко | Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application |
-
2011
- 2011-02-09 WO PCT/JP2011/052719 patent/WO2011099507A1/en active Application Filing
- 2011-02-09 RU RU2012138445/04A patent/RU2557237C2/en active
- 2011-02-09 BR BR112012020110-7A patent/BR112012020110B1/en active IP Right Grant
- 2011-02-09 US US13/577,832 patent/US9169266B2/en active Active
- 2011-02-09 NZ NZ601684A patent/NZ601684A/en unknown
- 2011-02-09 KR KR1020127021797A patent/KR101631143B1/en active IP Right Grant
- 2011-02-09 MX MX2012009323A patent/MX2012009323A/en active IP Right Grant
- 2011-02-09 SG SG2012059002A patent/SG183243A1/en unknown
- 2011-02-09 ES ES11742250.1T patent/ES2502740T3/en active Active
- 2011-02-09 CA CA2788533A patent/CA2788533C/en active Active
- 2011-02-09 JP JP2011553858A patent/JP5337261B2/en active Active
- 2011-02-09 AU AU2011215250A patent/AU2011215250B2/en active Active
- 2011-02-09 TW TW100104240A patent/TWI555751B/en active
- 2011-02-09 CN CN201180009003.6A patent/CN102753557B/en active Active
- 2011-02-09 EP EP11742250.1A patent/EP2535342B1/en active Active
-
2012
- 2012-08-06 IL IL221325A patent/IL221325A/en active IP Right Grant
-
2015
- 2015-09-28 US US14/867,501 patent/US9737539B2/en active Active
-
2017
- 2017-07-12 US US15/647,911 patent/US10016433B2/en active Active
-
2018
- 2018-06-27 US US16/020,436 patent/US10576084B2/en active Active
-
2020
- 2020-01-21 US US16/747,603 patent/US20200390768A1/en not_active Abandoned
-
2022
- 2022-09-26 FR FR22C1049C patent/FR22C1049I2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1049I1 (en) | CONDENSED HETEROCYCLIC DERIVATIVE SALT AND CRYSTALS THEREOF | |
| CY2021001I2 (en) | HETEROCYCLIC AMIDE DERIVATIVES USEFUL AS MICROBIOTICIDES | |
| LTC2447254I2 (en) | CRYSTALS | |
| DK2594567T3 (en) | HETEROCYCLIC ALKYNYLBENZENE COMPOUNDS AND USES THEREOF | |
| DK2880447T3 (en) | Markers associated with sensitivity to human double minute 2 inhibitors (MDM2) | |
| IL242278A (en) | Substituted n-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin-2-amine compounds and salts thereof | |
| HK1199725A1 (en) | Heterocyclic compounds and uses thereof | |
| HK1198475A1 (en) | Heterocyclic compounds and uses thereof | |
| HK1198443A1 (en) | Heterocyclic compounds and uses thereof | |
| DK2920168T3 (en) | HETEROCYCLIC GLUTAMINASE INHIBITORS | |
| SG11201503042QA (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
| HK1193561A1 (en) | Heterocyclic compounds and uses thereof | |
| CO6910189A2 (en) | Heterocyclic and pharmaceutical derivative | |
| DK2782570T3 (en) | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | |
| DK2540728T3 (en) | Heterocyclic compound | |
| BR112012008061A2 (en) | heterocyclic oxime compounds | |
| EP2759533A4 (en) | Condensed heterocyclic compound | |
| BR112013014943A2 (en) | compounds useful for the treatment of AIDS | |
| IL227664A0 (en) | Novel heterocyclic derivatives | |
| DK2782618T3 (en) | TRANSPLANT FOR USE WITH MODPULSATION DEVICE | |
| DK3777876T3 (en) | N-acyl dipeptide derivatives and uses thereof | |
| BR112014009006A2 (en) | heterocyclic compounds and methods of use thereof | |
| SMT201600031B (en) | HETEROCYCLIC COMPOUNDS OF PHENOSSIMETHYL | |
| BR112013010643A2 (en) | heterocyclic compounds | |
| DK3392252T3 (en) | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND THEIR USE |